International Niemann–Pick Disease Alliance

Updates

  1. Loire Valley 2018 – Info Pack

    Available for download, here. 

    Read story
  2. Niemann-Pick Disease Type C (NP-C) Gene Therapy Activation Meeting (GAM)

    Manoir de Clénord, Chambord, France October 18-19, 2018 The following report summarizes discussions at the NP-C Gene Therapy Activation Meeting (GAM), a first-of-its-kind satellite meeting to the bi-annual Loire-Valley Meeting (LVM) hosted by the German and Swiss Niemann-Pick family...

    Read story
  3. Orphazyme Reports Encouraging Arimoclomol Clinical Trial Top-line Data in Niemann-Pick Disease Type C (NP-C)

    ORPHAZYME REPORTS ENCOURAGING ARIMOCLOMOL CLINICAL TRIAL TOP-LINE DATA IN NIEMANN-PICK DISEASE TYPE C (NPC) Arimoclomol was well-tolerated in patients with the rare disease NPC The NPC Phase II/III trial top-line results show a treatment benefit of arimoclomol over placebo...

    Read story
  4. What is the International Niemann-Pick Disease Registry (INPDR)?

    In the following video INPDA President and Former NPUK Trustee Jim Green defines what exactly the International Niemann-Pick Disease Registry (INPDR) is, and why it is needed: “…the International Niemann-Pick Disease Registry aims to collect data about the disease...

    Read story
  5. Chin Huei Wu (巫錦輝) – Taiwan Niemann-Pick Disease Patient Group

    Founder and Chair of the Taiwan Niemann-Pick Disease Patient Group, Chin Huei Wu (巫錦輝), gave a rousing presentation at the NPUK Annual Family Conference & Interactive Workshop on Niemann-Pick Disease (2017) in which he gave the story of his...

    Read story
  6. IMPORTANT: The Data Protection Law is Changing!

    Due to changes in data protection legislation, soon the International Niemann-Pick Disease Alliance (INPDA) won’t be able to contact you about any of our services or activities unless you explicitly give your consent. In other words, if you would like to...

    Read story
  7. FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol® Cyclo™ Trial for Niemann-Pick Disease Type C

    ALACHUA, FL – (Marketwired) – April 30, 2018 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that FDA has authorized its...

    Read story
  8. CTD Holdings Closes $2.00 Million Private Placement

    ALACHUA, FL — (Marketwired) — 04/23/18 — CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has closed a private placement...

    Read story
  9. CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol® Cyclo™ to Treat Niemann-Pick Disease Type C

    Initial data support safety and tolerability of Trappsol® Cyclo™ administered intravenously (Available for download, here) ALACHUA, FL – (Marketwired) – 03/29/2018 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment...

    Read story
  10. Update #18 on the Orphazyme AIDNPC Clinical Programme

    Update #18 on the AIDNPC clinical programme (arimoclomol in treatment of Niemann-Pick disease type C) Available for download in English, German, French, Spanish, Italian, and Polish.   Interim information bulletin (following the Dec. 28th call) SUMMARY 001 Study: Status...

    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...